Duloxetine compared with placebo for treating women with symptoms of overactive bladder

BJU International

Volumn 100, Issue 2, 2007, Pages 337-345

  Steers, William D ^a   Herschorn, Sender ^b   Kreder, Karl J ^c   Moore, Kate ^d   Strohbehn, Kris ^e   Yalcin, Ilker ^f   Bump, Richard C ^f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF IOWA   (United States)

^d ST GEORGE HOSPITAL   (Australia)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Duloxetine; Overactive bladder; Pharmacological treatment; Urge incontinence; Urinary frequency

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BOTHERSOMENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENDOMETRIUM CANCER; FATIGUE; FEMALE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MEASUREMENT; MICTURITION; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAFETY; STATISTICAL SIGNIFICANCE; STRESS INCONTINENCE; SYMPTOM; THERAPY EFFECT; URGE INCONTINENCE; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS; VITAL SIGN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; THIOPHENES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URODYNAMICS;

EID: 34447118412     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06980.x     Document Type: Article

References (21)

1. Abrams P, Cardozo L, Fall F et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78
2. Burgard EC, Fraser MO, Karicheti V, Ricca DJ, Thor KB. New pharmacological treatments for urinary incontinence and overactive bladder. Curr Opin Invest Drugs 2005 6 : 81 9
3. Thor KB, Katofiasc MA, Danuser H, Springer J, Schaus JM. The role of 5HT1A receptors in control of lower urinary tract function in cats. Brain Res 2002 946 : 290 7
4. Danuser H, Bemis K, Thor KB. Pharmacological analysis of noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat. J Pharmacol Exp Ther 1995 274 : 820 5
5. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995 274 : 1014 24
6. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002 187 : 40 8
7. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC Duloxetine Urinary Incontinence Study Group. Duloxetine vs placebo in the treatment of North American women with stress urinary incontinence. J Urol 2003 170 : 1259 63
8. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC, Duloxetine UI Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence: a four continent randomized clinical trial. BJU Int 2004 93 : 311 8
9. Van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 2004 111 : 249 57
10. Cardozo L, Drutz HP, Baygani SK, Bump RC, for the Duloxetine Severe UI Study Group. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004 104 : 511 9
11. Ghoniem GM, Van Leeuwen JS, Elser DM et al. for the Duloxetine/PFMT Clinical Trial Group. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence. J Urol 2005 173 : 1647 53
12. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology 1996 47 : 67 71
13. Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the Incontinence Quality of Life Instrument (I-QOL). Urology 1999 53 : 71 6
14. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003 189 : 98 101
15. Lubeck DP, Prebil LA, Peeples P, Brown JS. A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. Qual Life Res 1999 8 : 337 44
16. Hurley DJ, Turner CL, Yalcin I, Viktrup L, Saygani SK. Duloxetine for the treatment of stress urinary incontinence: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2006 125 : 120 8
17. Mulcahy JJ, Laddu AR, Faries DE et al. Efficacy and safety of duloxetine in stress incontinence patients. Neurourol Urodyn 1996 15 : 395 6
18. Malone-Lee J, Henshaw DJE, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 2003 92 : 415 7
19. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urol 1997 50 (Suppl. 90 6
20. Donovan J, Bosch R, Gotoh M et al. Symptom and quality of life assessment. In Abrams P, Cardozo L, Khoury S, Wein A. Incontinence. Paris : Health Publication Ltd., 2005 : 519 84
21. Castro-Diaz D, Palma PCR, Bouchard C, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int J Urogynecol 2007 in press. Epub ahead of print Dec 12 2006.